Raleigh Capital Management Inc. Pacira Bio Sciences, Inc. Transaction History
Raleigh Capital Management Inc.
- $253 Million
- Q4 2024
A detailed history of Raleigh Capital Management Inc. transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, Raleigh Capital Management Inc. holds 537 shares of PCRX stock, worth $14,139. This represents 0.0% of its overall portfolio holdings.
Number of Shares
537
Previous 537
-0.0%
Holding current value
$14,139
Previous $8,000
25.0%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding PCRX
# of Institutions
254Shares Held
48.5MCall Options Held
429KPut Options Held
391K-
Black Rock Inc. New York, NY8.01MShares$211 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.3MShares$140 Million0.0% of portfolio
-
Pacer Advisors, Inc. Malvern, PA3.26MShares$85.9 Million0.15% of portfolio
-
State Street Corp Boston, MA2.01MShares$53 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.98MShares$52.1 Million0.05% of portfolio
About Pacira BioSciences, Inc.
- Ticker PCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 45,824,200
- Market Cap $1.21B
- Description
- Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...